耐多药结核病患者利奈唑胺群体药代动力学与靶标达成分析
本研究基于39例耐多药结核患者244份利奈唑胺血药浓度样本建立群体药代动力学模型,评估不同给药方案的PK/PD靶标达成概率。结果显示300 mg每日两次在MIC 0.5 mg/L时PTA仅55%,而600 mg每日两次达97%;全球CFR≥90%仅在高剂量方案实现。提示300 mg每日两次可能不足,建议以600 mg每日两次起始并开展治疗药物监测与MIC测定。
要点
- 300 mg每日两次在MIC 0.5 mg/L时PTA仅55%,PK/PD角度可能不足以治疗MDR-TB。
- 600 mg每日两次在MIC 0.5 mg/L时PTA达97%,全球CFR可达≥90%。
- 利奈唑胺在结核人群PK变异大,建议开展治疗药物监测和MIC测定。
核心结论
- 从PK/PD角度,300 mg每日两次的利奈唑胺可能不足以治疗耐多药结核病患者。
- 建议以600 mg每日两次的较高剂量起始以确保PK/PD靶标达成。
- 应开展治疗药物监测和MIC测定以控制PK/PD靶标达成,因利奈唑胺在结核人群PK变异大。
研究设计与样本
- 基于39例耐多药结核患者共244份定时利奈唑胺血药浓度样本,采用NONMEM 7.4建立药代计量学模型。
- 估计不同给药方案的靶标达成概率(PTA,靶标为游离AUC/MIC=119)及地区特异性累积反应分数(CFR)。
主要发现
- 最终模型为一室线性消除模型,清除率7.69 L/h(个体间变异34.1%),分布容积45.2 L,吸收常数0.679 h-1(周期间变异143.7%),按体重异速缩放。
- MIC 0.5 mg/L时,300 mg每日两次的PTA为55%,600 mg每日两次的PTA为97%。
- CFR在不同人群和地理区域间差异很大。
- 全球CFR≥90%仅在600 mg每日两次给药时实现,300 mg每日两次未达到。
关键数值与推荐
- PK/PD靶标为游离AUC/MIC=119。
- MIC 0.5 mg/L时,300 mg每日两次PTA为55%,600 mg每日两次PTA为97%。
- 全球CFR≥90%的目标在600 mg每日两次时达成,300 mg每日两次未达成。
临床怎么用
- 对耐多药结核病患者,可考虑以利奈唑胺600 mg每日两次起始而非300 mg每日两次以确保PK/PD靶标达成。
- 治疗期间应开展治疗药物监测和MIC测定,因利奈唑胺在结核人群PK变异大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: This study investigates the pharmacokinetic/pharmacodynamic (PK/PD) target attainment of linezolid in patients infected with multidrug-resistant (MDR) tuberculosis (TB). METHODS: A pharmacometric model was developed including 244 timed linezolid concentration samples from 39 patients employing NONMEM 7.4. The probability of target attainment (PTA, PK/PD target: unbound (f) area-under-the-concentration-time-curve (AUC)/minimal inhibitory concentration (MIC) of 119) as well as a region-specific cumulative fraction of response (CFR) were estimated for different dosing regimens. RESULTS: A one-compartment model with linear elimination with a clearance (CL) of 7.69 L/h (interindividual variability 34.1%), a volume of distribution (Vd) of 45.2 L and an absorption constant (KA) of 0.679 h-1 (interoccasion variability 143.7%) allometric scaled by weight best described the PK of linezolid. The PTA at an MIC of 0.5 mg/L was 55% or 97% if patients receiving 300 or 600 mg twice daily, respectively. CFRs varied greatly among populations and geographic regions. A desirable global CFR of ≥90% was achieved if linezolid was administered at a dose of 600 mg twice daily but not at a dose of 300 mg twice daily. CONCLUSION: This study showed that a dose of 300 mg twice daily of linezolid might not be sufficient to treat MDR-TB patients from a PK/PD perspective. Thus, it might be recommendable to start with a higher dose of 600 mg twice daily to ensure PK/PD target attainment. Hereby, therapeutic drug monitoring and MIC determination should be performed to control PK/PD target attainment as linezolid shows high variability in its PK in the TB population.
引用
- Tietjen AK, Kroemer N, Cattaneo D, et al. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients. Br J Clin Pharmacol. 2021. PMID: 34622478. doi:10.1111/bcp.15102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。